In this work the authors have reported the case of a patient who suffers from medication-related osteonecrosis of the jaw after the administration of Denosumab (Prolia). Meanwhile, the authors compiled and listed the related literatures, and reviewed these literatures. This paper gives a detailed summary of the definition, pathophysiological mechanism, risk factor, clinical treatment and prevention strategies of MRONJ. However, several drawbacks are needed to be improved.

Major points:

1. In the part of introduction, the authors only focus on osteoporosis, and overlooked the introduction of medication-related osteonecrosis of the jaw and the related drugs such as Denosumab and diphosphonate. In addition, the association between osteoporosis and medication-related osteonecrosis of the jaw needs to be described in this part.
2. The authors explained many irrelevant contents such as the definition of osteoporosis and MRONJ. These contents are not related to the part “Timing of referral for medication-related osteonecrosis of the jaw”.
3. This paper lacks the record and detailed description of the cases, and does not provide first-hand and effective information on the manifestations, mechanism, diagnosis and treatment of MRONJ.
4. The etiology, pathology, clinical manifestations, diagnosis and treatment of MRONJ need to be discussed with reference to related case.
5. In the part of conclusion, it is better to make necessary statements around the reported cases, clarify the author's point of view or suggest new ideas.